Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?

医学 食管切除术 食管癌 倾向得分匹配 放化疗 外科 入射(几何) 癌症 内科学 疾病 吻合 总体生存率 物理 光学
作者
Sheraz R. Markar,Caroline Gronnier,Alain Duhamel,Arnaud Pasquer,Jérémie Thereaux,M. Chalret du Rieu,Jérémie H. Lefèvre,Kathleen Turner,Guillaume Luc,C. Mariette
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:33 (33): 3866-3873 被引量:189
标识
DOI:10.1200/jco.2014.59.9092
摘要

Purpose The aim of this large multicenter study was to assess the impact of salvage esophagectomy after definitive chemoradiotherapy (SALV) on clinical outcome. Patients and Methods Data from consecutive adult patients undergoing resection for esophageal cancer in 30 European centers from 2000 to 2010 were collected. First, groups undergoing SALV (n = 308) and neoadjuvant chemoradiotherapy followed by planned esophagectomy (NCRS; n = 540) were compared. Second, patients who benefited from SALV for persistent (n = 234) versus recurrent disease (n = 74) were compared. Propensity score matching and multivariable analyses were used to compensate for differences in some baseline characteristics. Results SALV versus NCRS groups: In-hospital mortality was similar in both groups (8.4% v 9.3%). The only significant differences in complications were seen for anastomotic leak (17.2% v 10.7%; P = .007) and surgical site infection, which were both more frequent in the SALV group. At 3 years, groups had similar overall (43.3% v 40.1%; P = .542) and disease-free survival (39.2% v 32.8%; P = .232) after matching, along with a similar recurrence pattern. Persistent versus recurrent disease groups: There were no significant differences between groups in incidence of in-hospital mortality or major complications. At 3 years, overall (40.9% v 56.2%; P = .046) and disease-free survival (36.6% v 51.6%; P = .095) were lower in the persistent disease group. Conclusion The results of this large multicenter study from the modern era suggest that SALV can offer acceptable short- and long-term outcomes in selected patients at experienced centers. Persistent cancer after definitive chemoradiotherapy seems to be more biologically aggressive, with poorer survival compared with recurrent cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
JinYan发布了新的文献求助10
1秒前
XYX发布了新的文献求助20
1秒前
1秒前
wyy发布了新的文献求助10
1秒前
1秒前
冷酷向日葵完成签到,获得积分10
1秒前
随机昵称过于可爱完成签到,获得积分10
1秒前
2秒前
2秒前
2秒前
夫子完成签到,获得积分10
2秒前
龙龙龙完成签到,获得积分10
2秒前
0318完成签到,获得积分10
3秒前
3秒前
齐一诺完成签到 ,获得积分10
3秒前
4秒前
MW发布了新的文献求助10
4秒前
4秒前
韩小青发布了新的文献求助10
4秒前
4秒前
4秒前
凌万完成签到 ,获得积分10
4秒前
kele完成签到,获得积分10
4秒前
Nacl_ni发布了新的文献求助10
5秒前
5秒前
在水一方的应助被Queena采纳,获得10
5秒前
5秒前
小鹿5460发布了新的文献求助10
5秒前
5秒前
5秒前
lobster发布了新的文献求助10
5秒前
ss完成签到,获得积分10
6秒前
李航完成签到,获得积分10
6秒前
6秒前
龙龙龙发布了新的文献求助10
6秒前
lcsw发布了新的文献求助10
6秒前
6秒前
桐桐的应助被jsjs采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162373
求助须知:如何正确求助?哪些是违规求助? 9556708
关于积分的说明 21736348
捐赠科研通 7752651
什么是DOI,文献DOI怎么找? 3427713
关于科研通互助平台的介绍 2552691
邀请新用户注册赠送积分活动 2472338